KOL Perspectives: Histologic Healing in Crohn's disease

Summary

This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn’s disease.

Questions topics -

• Use of histological assessment in clinical trials and practice in Crohn’s disease


• Extrapolation of UC histology to UC


• Barriers to adoption of histology assessment in Crohn’s disease


• Impact of histological data in therapy choice in Crohn’s diseaseꟷViews on use of Geboes as an endpoint in Crohn’s disease


• Views on Phase II sub-analysis data for filgotinib

Key Highlights

• Majority of KOLs state that histologic healing is not used to assess Crohn’s disease patients in clinical practice


• Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal


• Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.

Scope

• The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

• 5 Europe-based & 5 N. America-based


• Interviews performed during Q2 2018

KOL data is analyzed to produce -

• Charts summarizing KOL opinions


• Chart call-outs of key information & details


• KOL quotes


• Summary of KOL reporting trends


• Insight from Sociable Pharma's analysts

Reasons to Buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn’s disease


• Includes insight & recommendations from our disease-specific healthcare analysts


• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD


• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.